$7.50 per share
Myeloid Therapeutics and MaxCyte Enter Clinical and Commercial Licensing Agreement to Advance Myeloid’s Cell Therapy Programs
Patented high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology.
The Sixth Annual BioHealth Capital Region Forum brought together industry leaders from across the region who discussed the accomplishments and strengths of the region as its member companies continue to innovate new therapies and medicines in one of the strongest bio-hub regions in the United States.
Experts Weigh in on the Role of Lab Automation and Sensor Technology in Advancing the Cell Therapy and Regenerative Medicine Fields
While there is tremendous excitement and ample investment around cell and gene therapy and regenerative medicine, several challenges, including scale-up, high manufacturing costs, and regulatory hurdles, continue to be impediments to the industry achieving its potential.
Mike O’Mara has more than 27 years of experience in biopharmaceutical contract manufacturing encompassing microbial, mammalian, and cell/Gene therapy manufacturing processes ranging from Preclinical/Phase I through Commercial.
Amanda L. Murphy Appointed as Chief Financial Officer to MaxCyte
Kite Seeking to Hire Cell Therapy Talent Ahead of Opening Its New Advanced Biomanufacturing Facility in Frederick, Maryland
A year and a half after announcing their plans to build a state-of-the-art cell manufacturing facility in Frederick County, Maryland, Kite, a Gilead Company, is looking to fill dozens of new biomanufacturing jobs in Maryland and add to the talented site team it already has in place.
Jeff Galvin is the CEO and Founder of American Gene Technologies™ (AGT). He earned his BA degree in Economics from Harvard in 1981 and has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of Silicon Valley startups.
Why Advanced Biomanufacturing in Maryland is a Thriving Industry These Four Industry-leading BioManufacturing Companies Represent Thousands of Jobs in Maryland and Are Shaping the Future of Medicine A burgeoning cell [….]
Bryan Poltilove is a Managing Director focused on guiding BroadOak’s growth capital investing strategy and advising portfolio companies in the life sciences and cell and gene therapy sectors.